Bicara Therapeutics Inc (BCAX)

Apr 03, 2025

FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World

Apr 03, 2025

Mar 31, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com

Mar 31, 2025

Mar 31, 2025

Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks

Mar 31, 2025

Mar 31, 2025

Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World

Mar 31, 2025

Mar 29, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World

Mar 29, 2025

Mar 28, 2025

Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 28, 2025

Mar 28, 2025

Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 28, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks

Mar 28, 2025

Mar 28, 2025

Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025

Mar 27, 2025

Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India

Mar 27, 2025

Mar 27, 2025

Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 27, 2025

Mar 27, 2025

Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - MarketScreener

Mar 27, 2025

Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle

Mar 27, 2025

Mar 26, 2025

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewswire

Mar 26, 2025

Mar 18, 2025

Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Mar 18, 2025

Mar 15, 2025

Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register

Mar 15, 2025

Mar 15, 2025

Cantor Fitzgerald Reiterates “Overweight” Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Mar 15, 2025

Mar 14, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Price Target from Analysts - Defense World

Mar 14, 2025

Mar 13, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics By Investing.com - Investing.com Canada

Mar 13, 2025

Mar 13, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics - Investing.com India

Mar 13, 2025

Mar 12, 2025

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Yahoo Finance

Mar 12, 2025

Mar 10, 2025

19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline Advisers - Defense World

Mar 10, 2025

Mar 05, 2025

Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th - Defense World

Mar 05, 2025

Feb 24, 2025

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 24, 2025

Feb 21, 2025

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Feb 21, 2025

Feb 17, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Feb 17, 2025

Feb 17, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World

Feb 17, 2025

Feb 16, 2025

Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com

Feb 16, 2025

Feb 16, 2025

Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat

Feb 16, 2025

Feb 15, 2025

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat

Feb 15, 2025

Feb 14, 2025

Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat

Feb 14, 2025

Feb 14, 2025

Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Feb 14, 2025

Feb 11, 2025

Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire

Feb 11, 2025

Feb 11, 2025

Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan

Feb 11, 2025

Feb 11, 2025

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Investing.com UK

Feb 11, 2025

Feb 11, 2025

Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat

Feb 11, 2025

Feb 10, 2025

Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World

Feb 10, 2025

Feb 09, 2025

Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat

Feb 09, 2025

Feb 08, 2025

Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Feb 08, 2025

Feb 07, 2025

Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter

Feb 07, 2025

Feb 07, 2025

Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat

Feb 07, 2025

Feb 06, 2025

Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq

Feb 06, 2025

Feb 06, 2025

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com

Feb 06, 2025

Feb 04, 2025

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat

Feb 04, 2025

Feb 03, 2025

Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN

Feb 03, 2025